Dent P B, Louis J A, McCulloch P B, Dunnett C W, Cerottini J C
Cancer. 1980 Jan 1;45(1):130-6. doi: 10.1002/1097-0142(19800101)45:1<130::aid-cncr2820450123>3.0.co;2-7.
The presence of immune complexes and carcinoembryonic antigen (CEA) was investigated in 50 patients with bronchogenic carcinoma at the time of and/or following diagnostic or definitive surgery. Immune complexes were measured by the C1q binding test and CEA by the Z gel method and elevations defined as values in excess of 2 S.D. above the normal mean, greater than or equal to 9.2% for C1q binding activity (C1q-BA) and greater than or equal to 5.0 ng/ml for CEA. The overall incidence of elevated values was 30.7% for C1q-BA and 34.2% for CEA. There was a greater incidence of elevated values of C1q-BA among patients with clinically evident disease. The differences with respect to CEA elevation were not significant due to the fact that 6 of 9 samples with elevated CEA values obtained from patients with no evident disease were in fact associated with the presence of clinically undetectable disease in these patients. Elevation of C1q-BA and CEA beyond the immediate postoperative period was predictive of a significantly shorter median survival time. The most significant differences in survival time were seen between patients with normal values for C1q-BA and CEA and those with elevations of one or both parameters, 6.0 vs. 19.5 months (p less than 0.001). Elevation of either parameter during the immediate pre- and postoperative period was not predictive of a poor survival. In terms of clinical application, it appears that CEA estimation had the best predictive value but that the addition of C1q-BA measurement may provide additional prognostic information, particularly in patients who do not have elevated CEA values.
在50例支气管源性肺癌患者诊断性手术时和/或根治性手术后,对免疫复合物和癌胚抗原(CEA)进行了检测。免疫复合物采用C1q结合试验测定,CEA采用Z凝胶法测定,升高定义为超过正常均值2个标准差的值,C1q结合活性(C1q-BA)大于或等于9.2%,CEA大于或等于5.0 ng/ml。C1q-BA值升高的总体发生率为30.7%,CEA为34.2%。临床症状明显的患者中C1q-BA值升高的发生率更高。CEA升高方面的差异不显著,因为从无明显疾病患者中获得的9份CEA值升高的样本中有6份实际上与这些患者存在临床无法检测到的疾病有关。术后即刻C1q-BA和CEA升高预示中位生存时间显著缩短。C1q-BA和CEA值正常的患者与一项或两项参数升高的患者之间生存时间差异最为显著,分别为6.0个月和19.5个月(p<0.001)。术前和术后即刻任一参数升高均不能预测生存不良。就临床应用而言,似乎CEA评估具有最佳预测价值,但增加C1q-BA测量可能提供额外的预后信息,特别是在CEA值未升高的患者中。